Prospective multicenter study to measure the impact of MMprofiler on treatment intention in active multiple myeloma patients
Study to Measure the Impact of MMprofiler on Treatment Intention in Multiple Myeloma Patients (PROMMIS)
Sponsor: SkylineDx, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAR4254
U.S. Govt. ID: NCT02911571
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: We are doing this study to learn if the MMprofiler test can help your doctor in making decisions about your treatment. The MMprofiler genomic test will look at a large number of normal genes. The test will predict risk of your multiple myeloma (MM) by assessing whether these genes are turned on or off in your cancer cells. The purpose of this research is to study whether this test can help your doctor to determine what treatment will be best for your multiple myeloma.
This study is closed
Investigator
Suzanne Lentzsch, MD
Do You Qualify?
Are you 18 years or older? Yes No
Do you have potentially active/active multiple myeloma? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162